Long Duration Therapeutic Ultrasound on Tendon Injuries
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Tendon Injuries
- Sponsor
- ZetrOZ, Inc.
- Enrollment
- 13
- Locations
- 2
- Primary Endpoint
- Change in pain on the visual analog scale (VAS) from baseline to study conclusion
- Status
- Terminated
- Last Updated
- 9 years ago
Overview
Brief Summary
Human clinical trial to measure the effect of long duration therapeutic ultrasound on tendon injuries. The hypothesis is that use of long duration ultrasound will relieve pain, increase tendon strength, and improve quality of life for patients with tendon injury.
Detailed Description
The ability of long duration therapeutic ultrasound to reduce pain, increase strength, and improve quality of life for patients with tendon injury \[e.g. tendinopathy of the elbow (medial or lateral\], Achilles tendon, or patellar tendon) will be assessed. During the 7-week protocol, participants will receive 4 continuous hours of therapy daily. For the first week, baseline data will be collected as participants report pain scores (VAS) in the morning, noon, and night. During the next 6 weeks, participants will self-apply the device each day and record their pain score (VAS) before and treatment; and record their pain score (VAS) while performing specified movements designed to evaluate tendon rehabilitation. At bi-weekly site visits, strength measurements will be performed on the injured and uninjured limb. Participants will also complete a standardized questionnaire to assess disability due to the specific tendon injury at baseline and study conclusion.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Has been diagnosed with tendinitis in the elbow (medial or lateral epicondyles), patella, or Achilles tendon based on physical examination by a healthcare practitioner and medical history. Physical examination must include one of the following: assessment of pain during manual movements of the injured limb (e.g. a positive Mill's Test \[Wadsworth, 1987\] for elbow tendinitis), or local tenderness upon palpation over the tendon
- •Experience tendon pain greater than 1 (using the VAS scale of 0-10) during the week preceding study screening
- •Between 18 and 70 years of age
- •Willing and able to self-administer the study device to the treatment area daily
- •Have access to a mobile phone or camera to take a picture of the treatment area immediately after use of the device
- •Body Mass Index (BMI) is less than or equal to 34.0
- •Agree to document all pain medications and associated dosages during participation in the study.
- •If taking prescription pain medication, agree to keep dosage constant (unchanged) during participation in the study.
- •Agree not to use any topical solution such as analgesic cream or ointment on the treatment area during participation in the study
Exclusion Criteria
- •Subjects that cannot speak, read or write English
- •History or current diagnosis of tendinosis or a tendon tear
- •Known neuropathy (nerve damage that affects the treatment area)
- •Surgery in the treatment area within the last 6 months
- •Non-ambulatory (unable to walk)
- •Have a pacemaker
- •Malignancy in the treatment area
- •Refuse to discontinue all other interventional treatment modalities (i.e. transcutaneous electrical nerve stimulation (TENS), electrical stimulation, or other ultrasound therapy) during the study
- •Local corticosteroid or platelet-rich plasma (PRP) injection within the past 3 months
- •Clinically significant or unstable medical or psychological conditions that would compromise participation in the study
Outcomes
Primary Outcomes
Change in pain on the visual analog scale (VAS) from baseline to study conclusion
Time Frame: Baseline, Week 7
Secondary Outcomes
- Change in strength of limb through dynamometry(Baseline, Week 7)
- Quality of life and functioning through limb-specific standardized questionnaires(Baseline, Week 7)
- Pressure point sensitivity as measured through algometry(Baseline, Week 7)
- Change in pain during functional testing as measured by VAS(Baseline, Week 7)